The Stanford SAINT Protocol - SNT Trial
The Stanford SAINT Protocol SNT Trial (Cole et al., 2022)
The Stanford SAINT Protocol SNT Trial (Cole et al., 2022)
What this study was
Who was studied
What the protocol involved
What the results showed
What it means and what it doesn't
Why this study matters for patients
What this study was
The Stanford Neuromodulation Therapy trial, commonly called the SAINT study or SNT trial, is the most rigorous published evaluation of accelerated iTBS for treatment-resistant depression. It was a double-blind, randomized, sham-controlled trial, meaning neither patients nor the clinical staff administering treatment knew who was receiving real stimulation and who was receiving inactive sham treatment. It was conducted at Stanford University and published in JAMA Psychiatry, one of the most respected peer-reviewed journals in psychiatry.
Who was studied
The trial enrolled 29 patients with treatment-resistant major depressive disorder patients who had failed to respond adequately to at least one antidepressant trial. Participants were randomly assigned to receive either active SNT treatment or sham treatment. The two groups were well-matched at baseline for depression severity and prior treatment history.
What the protocol involved
The active treatment protocol delivered 10 iTBS sessions per day across five consecutive days 50 sessions total. Each iTBS session consisted of 1,800 pulses delivered over approximately three minutes. Sessions were spaced 50 minutes apart. The stimulation target was the left dorsolateral prefrontal cortex, individualized using functional MRI connectivity mapping to identify each patient's optimal stimulation site.
What the results showed
The results were striking by any standard in treatment-resistant depression research:
78.6% remission rate in the active treatment group at day 5, measured by the Montgomery-Åsberg Depression Rating Scale 13.3% remission rate in the sham group confirming the effect was not placebo Mean time to remission: 2.6 days with many patients showing meaningful response before the protocol was even complete Remission rates remained significantly higher in the active group at the one-month follow-up assessment
What it means and what it doesn't
This is a small trial 29 patients, and its results have not yet been fully replicated at scale in the general population. The original protocol used individualized fMRI-guided targeting, which is not standard at most TMS clinics including ours. Our Five-Day Intensive uses validated scalp-based targeting rather than fMRI, which is how the large majority of TMS providers operate in clinical practice.
The study's findings represent the strongest single piece of published evidence for accelerated TMS efficacy to date. They cannot be taken as a guarantee of individual outcomes, but they establish a meaningful and reproducible signal that accelerated iTBS produces remission in treatment-resistant depression at rates substantially above what traditional once-daily TMS achieves.
Why this study matters for patients
Before the SAINT trial, the best available evidence for TMS came from traditional once-daily protocols with real-world remission rates of approximately 30–35%. The SAINT results achieved in a treatment-resistant population, in five days, in a double-blind controlled trial fundamentally changed the evidence landscape for accelerated TMS. It is the primary reason the field has moved rapidly toward accelerated protocols and the primary reason we offer the Five-Day Intensive at Optimal TMS.
Full text available at: https://doi.org/10.1176/appi.ajp.2021.20101429
Source:
